Insmed Incorporated

This study tested a new tablet called brensocatib in 29 adults with cystic fibrosis. The goal was to see how the drug behaves in the body and if it is safe compared to a placebo over 4 weeks. Participants had stable lung function and continued their usual treatments.

This study tested an inhaled medication called treprostinil palmitil in 102 adults with pulmonary arterial hypertension (PAH), a condition where high blood pressure in the lungs makes it hard to breathe and move. The goal was to see if the drug could lower resistance in lung bloo…

This study tested a new inhaled medicine called ALIS (amikacin liposome inhalation suspension) for people with a hard-to-treat lung infection caused by MAC bacteria. About 425 adults took part, receiving either ALIS or a placebo along with standard antibiotics. The main goal was …

This study tested a once-daily pill called brensocatib in 1767 adults with non-cystic fibrosis bronchiectasis, a lung condition that causes chronic cough and frequent infections. The goal was to see if the drug could reduce the number of serious lung flare-ups (pulmonary exacerba…

This study checked the long-term safety of an inhaled powder drug (treprostinil palmitil) in 31 people with pulmonary hypertension caused by interstitial lung disease. Participants had already completed a previous study of the same drug. The main goal was to see how many had side…

This study tested a drug called brensocatib in 288 adults with chronic sinusitis but no nasal polyps. Participants took either 10 mg, 40 mg, or a placebo daily for 24 weeks. The goal was to see if the drug improves daily sinus symptoms like congestion, runny nose, and facial pain…

This study tested two different versions of an inhaled drug (TPIP) in 42 healthy adults to see how well each is absorbed by the body. Participants inhaled a single dose of each version on separate days. The goal was to gather information for future development, not to treat any d…